EUVIMEDEUVIMED entdecken
Crossref

Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.

LOVIT-COVID Investigators, On Behalf Of The Canadian Critical Care Trials Group, Adhikari, Neill KJ, Hashmi, Madiha, Tirupakuzhi Vijayaraghavan, Bharath Kumar, Rashan Haniffa, Abi Beane, Webb, Steve A und 48 weitere

Apollo (University of Cambridge) · 08.11.2023

DOI: 10.17863/cam.102297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apollo (University of Cambridge), erschienen am 08.11.2023. Verfasst von LOVIT-COVID Investigators und 59 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IMPORTANCE: The efficacy of vitamin C for hospitalized patients with COVID-19 is uncertain. OBJECTIVE: To determine whether vitamin C improves outcomes for patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Two prospectively harmonized randomized clinical trials enrolled critically ill patients receiving organ support in intensive care units (90 sites) and patients who were not critically ill (40 sites) between July 23, 2020, and July 15, 2022, on 4 continents. INTERVENTIONS: Patients were randomized to receive vitamin C administered intravenously or control (placebo or no vitamin C) every 6 hours for 96 hours (maximum of 16 doses). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of organ support-free days defined as days alive and free of respiratory and cardiovascular organ support in the intensive care unit up to day 21 and survival to hospital discharge. Values ranged from -1 organ support-free days for patients experiencing in-hospital death to 22 organ support-free days for those who survived without needing organ support. The primary analysis used a bayesian cumulative logistic model. An odds ratio (OR) greater than 1 represented efficacy (improved survival, more organ support-free days, or both), an OR less than 1 represented harm, and an OR less than 1.2 represented futility. RESULTS: Enrollment was terminated after statistical triggers for harm and futility were met. The trials had primary outcome data for 1568 critically ill patients (1037 in the vitamin C group and 531 in the control group; median age, 60 years [IQR, 50-70 years]; 35.9% were female) and 1022 patients who were not critically ill (456 in the vitamin C group and 566 in the control group; median age, 62 years [IQR, 51-72 years]; 39.6% were female). Among critically ill patients, the median number of organ support-free days was 7 (IQR, -1 to 17 days) for the vitamin C group vs 10 (IQR, -1 to 17 days) for the control group (adjusted proportional OR, 0.88 [95% credible interval {CrI}, 0.73 to 1.06]) and the posterior probabilities were 8.6% (efficacy), 91.4% (harm), and 99.9% (futility). Among patients who were not critically ill, the median number of organ support-free days was 22 (IQR, 18 to 22 days) for the vitamin C group vs 22 (IQR, 21 to 22 days) for the control group (adjusted proportional OR, 0.80 [95% CrI, 0.60 to 1.01]) and the posterior probabilities were 2.9% (efficacy), 97.1% (harm), and greater than 99.9% (futility). Among critically ill patients, survival to hospital discharge was 61.9% (642/1037) for the vitamin C group vs 64.6% (343/531) for the control group (adjusted OR, 0.92 [95% CrI, 0.73 to 1.17]) and the posterior probability was 24.0% for efficacy. Among patients who were not critically ill, survival to hospital discharge was 85.1% (388/456) for the vitamin C group vs 86.6% (490/566) for the control group (adjusted OR, 0.86 [95% CrI, 0.61 to 1.17]) and the posterior probability was 17.8% for efficacy. CONCLUSIONS AND RELEVANCE: In hospitalized patients with COVID-19, vitamin C had low probability of improving the primary composite outcome of organ support-free days and hospital survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT04401150 (LOVIT-COVID) and NCT02735707 (REMAP-CAP).

Schlagwörter

vitamin Cintravenous vitamin CCOVID-19 pandemichospitalized patientscritically ill patientsorgan supportsurvivalintensive care unittrial terminationfutility

Zitieren

APA

Investigators, L., Group, O. B. O. T. C. C. C. T., Adhikari, KJ, N., Hashmi, Madiha, Vijayaraghavan, T., Kumar, B., Haniffa, R., Beane, A., Webb, A, S., Angus, C, D., Gordon, C, A., Cook, J, D., Guyatt, …, & Meredith (2023). Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. Apollo (University of Cambridge). https://doi.org/10.17863/cam.102297

Vancouver

Investigators L, Group OBOTCCCT, Adhikari, KJ N, Hashmi, Madiha, et al. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. Apollo (University of Cambridge). 2023. doi:10.17863/cam.102297

BibTeX
@article{Investigators2023,
  author = {Investigators, LOVIT-COVID and Group, On Behalf Of The Canadian Critical Care Trials and Adhikari and KJ, Neill and Hashmi and Madiha and Vijayaraghavan, Tirupakuzhi and Kumar, Bharath and Haniffa, Rashan and Beane, Abi and Webb and A, Steve and Angus and C, Derek and Gordon and C, Anthony and Cook and J, Deborah and Guyatt and H, Gordon and Berry, Lindsay R. and Lorenzi, Elizabeth and Mouncey, Paul R. and Au, Carly and Pinto and Ruxandra and Ménard, Julie and Sprague and Sheila and Masse, Marie-Hélène and Huang and T, David and Heyland and K, Daren and Nichol and D, Alistair and McArthur and J, Colin and Man, De and Angelique and Al-Beidh, Farah and Annane, Djillali and Anstey, Matthew and Arabi and M, Yaseen and Battista and Marie-Claude and Berry and Scott and Bhimani, Zahra and Bonten, M. J. M. and Bradbury and A, Charlotte and Brant, Emily B. and Brunkhorst and M, Frank and Burrell and Aidan and Buxton and Meredith},
  title = {Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials},
  journal = {Apollo (University of Cambridge)},
  year = {2023},
  doi = {10.17863/cam.102297}
}
Kostenlos starten →